four fda approvals, two priority reviews, and sabcs highlights
Published 8 years ago • 187 plays • Length 7:53Download video MP4
Download video MP3
Similar videos
-
7:23
fda approval in nsclc, priority review in sclc, 2018 sabcs highlights, and more
-
10:55
fda approvals in cinv and her2 breast cancer, priority review in myelofibrosis, and more
-
11:00
fda approval in her2 breast cancer, priority review in nsclc, and more
-
10:49
fda approvals in melanoma and breast cancer, and priority reviews in prostate cancer and more
-
10:10
priority review designation in pmbcl and 2017 sabcs and ash annual meeting highlights
-
10:55
fda approval in myeloma, label update in her2 breast cancer, and more
-
3:28
evo icl fda approval: amazing race
-
8:10
breast cancer stage 2a: my fifth chemo session | how it went and how i feel
-
1:46:57
dr. nicholas turner | what ctdna can tell us | sabcs 2022 | educational session
-
7:21
fda approval in breast cancer, breakthrough designations in aml and bladder cancer, and more
-
7:35
fda approval for abemaciclib
-
11:13
fda approval in her2 early breast cancer, fast track designation in tnbc, and more
-
1:49
fda approval of durvalumab for bladder cancer
-
1:49
sabcs22: sara tolaney, md, mph | dana-farber cancer institute
-
0:46
fda approval of second-dosing schedule of nivolumab
-
2:03
durvalumab fda approval for bladder cancer
-
3:19
fda approval of durvalumab for advanced bladder cancer
-
1:22
dr. pusztai on rationale for the i-spy 2 trial with durvalumab/olaparib combo in her2- breast cancer
-
13:22
palbociclib and breast cancer
-
10:01
fda approvals in prostate cancer and esophageal cancer, and promising breast cancer data
-
1:10
sabcs22: rachel freedman, md, mph | dana-farber cancer institute
-
0:44
what to look out for at sabcs 2022